| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Labcorp Holdings Inc.$261.19
-3.57 (-1.35%)
D 37Pipeline Score Diagnostics · Clinical
Market Cap
21.50 B
EPS
10.54
P/E Ratio
24.95 $
Value Trade
175.40 M
SEC Financials
Q1 2026Dilution Risk
Revenue
3.54 B
Operating CF
191.50 M
Total Assets
19.09 B
Total Liabilities
10.34 B
Equity
8.73 B
D/E Ratio
12,345
%
Week
%
1 Month
%
3 Month
%
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
1.18 B
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
May 4, 2026
Overview
Volume
104.07 K
52 Week Range
209.38 - 293.72
% held by Insiders
0.4 %
% held by Institutions
98.51 %
Enterprise Value
27.51 B
Total Shares
82.40 M
Short %
4.18 %
Float Shares
82.07 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
D37
Pipeline Score $530M
Pipeline ValueValuation Signal
3
Drugs Scored0.0x
rNPV / MCap Top 51%
Mid Cap (rank 444 of 905)
Percentile RankLabcorp Holdings Inc. faces pipeline headwinds (37/100), with $624M risk-adjusted pipeline value, led by VIT-2763 once a day in Beta-Thalassemia (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| VIT-2763 once a day Small molecule | Beta-Thalassemia | Phase 2 | NCT04364269 | 60% | $431M | COMPLETED | 35 | - | - | Nov 3, 2021 | - | Dec 14, 2023 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in LH
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Labcorp Holdings Inc. (LH) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
LH
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
LH
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
LH
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
LH Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
LH Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-LH
Jun 8, 2026GENFIT: NASHnext®, Powered by GENFIT's Non-invasive Diagnostic Technology NIS4®, Launched via Labcorp’s OnDemand Offering for Identification of At-Risk MASH
GENFIT has announced the launch of its NASHnext® test through Labcorp OnDemand, aimed at identifying patients with at-risk MASH. This non-invasive diagnostic tool, powered by GENFIT's NIS4® technology, allows for broader access to testing without the need for in-person visits. The initiative addresses significant diagnostic gaps in routine care, especially for patients with metabolic risk factors.
Read more →-LH
Jun 8, 2026GENFIT annonce que NASHnext® de Labcorp, basé sur sa technologie diagnostique non invasive NIS4® pour l’identification de la MASH à risque, est lancé via la plateforme « Labcorp OnDemand »
GENFIT has announced the launch of the NASHnext® test via Labcorp OnDemand, utilizing its proprietary NIS4® technology. This non-invasive diagnostic tool aims to identify patients at risk of Metabolic dysfunction-Associated SteatoHepatitis (MASH). The initiative is designed to broaden access and facilitate early detection among a larger patient population, potentially benefiting millions in the U.S.
Read more →-LH
May 29, 2026Labcorp Supports Multi-Institution Trial to Expand Genetic Testing in Colorectal Cancer
Labcorp has announced a collaboration with the Alliance for Clinical Trials in Oncology to conduct a national trial aimed at enhancing germline genetic testing in colorectal cancer patients and their at-risk family members. The trial will explore proactive outreach by healthcare providers to improve testing rates and assess the impact of multigene panel testing on patient care. The study is sponsored by the National Cancer Institute and aims to generate real-world evidence to improve genetic risk identification.
Read more →-LH
May 28, 2026Labcorp Launches Expanded DPYD Test to Identify Cancer Patients at Risk for Severe Chemotherapy Side Effects
Labcorp has launched an expanded DPYD Genotyping test to identify cancer patients at risk of severe side effects from fluoropyrimidine chemotherapy. This test detects all DPYD variants recommended by the Association for Molecular Pathology, enabling safer and more personalized treatment. The initiative aims to reduce the risk of severe toxicity and improve patient outcomes in cancer care.
Read more →-LH
May 27, 2026Labcorp to Present at the Jefferies Global Healthcare Conference
Labcorp will present at the 2026 Jefferies Global Healthcare Conference on June 3. The presentation will be accessible via a live webcast and will be archived for later viewing. Labcorp is recognized for its comprehensive laboratory services, supporting a significant portion of new drug approvals.
Read more →-LH
Apr 22, 2026Labcorp Launches FDA-Approved Companion Diagnostic to Identify Patients with Ovarian Cancer Eligible for KEYTRUDA®
Labcorp has launched the PD-L1 IHC 22C3 pharmDx, the first FDA-approved companion diagnostic for identifying patients with platinum-resistant ovarian cancer eligible for KEYTRUDA. This diagnostic aims to improve treatment options for patients facing recurrence after initial therapy. With approximately 80% of ovarian cancer patients experiencing recurrence, this advancement could significantly impact survival outcomes.
Read more →-LH
Apr 14, 2026Children’s Hospital of Philadelphia and Labcorp Announce a Collaboration to Accelerate Access to Advanced Pediatric Diagnostics Nationwide
Labcorp and the Children's Hospital of Philadelphia have announced a strategic collaboration to enhance pediatric diagnostics across the U.S. This partnership aims to leverage CHOP's clinical expertise and Labcorp's diagnostic infrastructure to develop specialized tests for children. The initiative focuses on improving access to advanced diagnostics in areas such as oncology and metabolic diseases.
Read more →-LH
Apr 14, 2026Labcorp Introduces AI-Powered Real-World Data Platform with AWS and Datavant to Accelerate Alzheimer's Research
Labcorp has launched an AI-powered real-world data platform to enhance Alzheimer's research. Developed in collaboration with AWS and Datavant, this platform streamlines data analysis, allowing researchers to generate insights rapidly. With over 7.2 million Americans affected by Alzheimer's, this innovation aims to accelerate drug development and improve patient outcomes.
Read more →-LH
Apr 13, 2026Children's Hospital of Philadelphia and Labcorp Announce a Collaboration to Accelerate Access to Advanced Pediatric Diagnostics Nationwide
Labcorp and Children's Hospital of Philadelphia have announced a strategic collaboration to enhance pediatric diagnostics across the U.S. This partnership aims to leverage CHOP's clinical expertise and Labcorp's diagnostic capabilities to develop and distribute specialized tests for children. The initiative focuses on improving access to advanced diagnostics in areas like oncology and metabolic diseases.
Read more →-LH
Apr 1, 2026Labcorp to Announce First Quarter Financial Results on April 30, 2026
Labcorp Holdings Inc. is set to announce its first quarter financial results for 2026 on April 30, 2026. The announcement will occur before market opening, followed by a webcast at 9:00 a.m. ET. The earnings press release will be available on their Investor Relations website, along with a replay of the webcast.
Read more →-LH
Feb 23, 2026Labcorp Expands Collaboration with PathAI to Deploy FDA-Cleared Digital Pathology Platform Nationwide
Labcorp has announced an expanded collaboration with PathAI to deploy the FDA-cleared AISight® Dx digital pathology platform across its network of anatomic pathology labs. This initiative aims to enhance efficiency and patient care through AI-enabled insights and fully digital workflows. The partnership builds on a previous investment made in 2019, further advancing AI-driven clinical trial support.
Read more →-LH
Feb 17, 2026Labcorp Announces 2025 Fourth Quarter and Full Year Results
Labcorp Holdings Inc. reported strong financial results for the fourth quarter and full year of 2025, highlighting over 7% revenue growth and double-digit adjusted EPS growth. The company is optimistic about its performance in 2026, driven by advancements in its Diagnostics and Central Laboratory businesses. Additionally, Labcorp announced a cash dividend and significant stock repurchases.
Read more →-LH
Feb 11, 2026Labcorp Launches First FDA-Cleared Blood Test for Alzheimer’s Disease Assessment in Primary Care
Labcorp has launched the Elecsys pTau-181 test, the first FDA-cleared blood test for assessing Alzheimer's disease in primary care. This test enables primary care clinicians to rule out Alzheimer's by identifying patients unlikely to have amyloid pathology. It aims to facilitate earlier diagnosis and guide further testing for cognitive decline.
Read more →-LH
Jan 13, 2026Labcorp Expands MRD Testing for Breast, Lung and Colon Cancer Recurrence Risk
Labcorp has expanded its molecular residual disease (MRD) testing portfolio to include new tests for breast, lung, and colon cancer. The Labcorp Plasma Detect ID and Genome tests aim to detect cancer recurrence earlier than traditional methods by identifying circulating tumor DNA in the bloodstream. This expansion supports personalized care and improves patient access to non-invasive testing options.
Read more →-LH
Jan 9, 2026Visby Engages Quest and Labcorp to Broaden Consumer Access to First At-Home, FDA-Authorized PCR Test for STIs
Visby Medical has partnered with Quest Diagnostics and Labcorp to enhance access to its at-home Women's Sexual Health Test, the first FDA-authorized PCR test for STIs. This test provides lab-quality results in just 30 minutes, allowing for immediate treatment options. The collaboration aims to address the urgent need for accessible STI testing, particularly for women, who often face barriers to care.
Read more →-LH
Jan 9, 2026NAMSA Announces Strategic Acquisition of Select Assets of the Early Development Medical Device Testing Business of Labcorp
NAMSA has successfully acquired the Early Development medical device testing business from Labcorp, enhancing its service offerings for MedTech manufacturers. This acquisition allows NAMSA to provide a broader range of testing and regulatory consulting services, while Labcorp can concentrate on its primary areas of drug development. The transition aims to maintain high service levels for existing Labcorp clients.
Read more →Competitive Position
How LH ranks across every disease it competes inCompetitive Position is a premium feature
See how LH ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial